The Medicines for Human Use (Clinical Trials) Regulations 2004

[F1List of countries for the purpose of the definition of “marketing authorization” on IP completion day (regulation 2A)U.K.

1.(1) For the purpose of regulation 2A, during the transitional period, the licensing authority must include each EEA State in the list referred to in paragraph (1) of that regulation.

(2) Notwithstanding regulation 2A(3), the licensing authority must not, before the end of the transitional period, remove an EEA State from the list referred to in regulation 2A(1).

(3) In this paragraph, “transitional period” is the period of two years beginning with IP completion day.]